*Corresponding Author: devia@srmist.edu.in 15 DOI: https://doi.org/10.52756/ ijerr.2024.v39spl.002 Int. J. Exp. Res. Rev., Vol. 39: 15-38 (2024) Integrated Bioinformatics Analysis and Transcriptomics Analysis Predict Jumonji and AT Rich Interacting Domain2 (JARID2) as a Therapeutic Target in Human Cancers Bhuvanadas Sreeshma 1 , Habeeb Shaik Mohideen 2 and Arikketh Devi 1 * 1 Stem Cell Biology and Cancer Biology Laboratory, Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu District, Tamilnadu, India; 2 Bioinformatics and Entomoinformatics Laboratory, Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu District, Tamilnadu, India E-mail/Orcid Id: BS, sb3123@srmist.edu.in, https://orcid.org/0000-0002-7645-889X; HSM, habeebm@srmist.edu.in, https://orcid.org/0000-0003-4217-5063; AD, devia@srmist.edu.in, https://orcid.org/0000-0002-8542-3760 Introduction Cancer is the most common disease, with high morbidity and excessive rates of mortality worldwide (Kesavan et al., 2023; Madhu et al., 2022, 2023). According to the cancer statistical reports by the World Health Organization, Asia is the most affected continent in 2020 (GCO, 2020). Each type of cancer possesses a unique molecular signature, which could be any alterations in genetic and epigenetic events (Li et al., 2011; Randall et al., 2014; Takeshima and Ushijima, 2019; Ghosh et al., 2024; Yadav et al., 2024). Apart from genetic aberrations, epigenetic changes play an inevitable role in promoting malignancy (You and Jones, 2012; Das et al., 2024; Halder, 2024). The cancer cells proliferate and perform metastasis via a trigger regulated by certain driver genes, which stimulate tumor growth. In cancer, the epigenetic aberrations are complicated, which include chromatin structure-based alterations involving DNA methylation, histone variants, and modifications, nucleosome remodeling, small non-coding regulatory RNA, etc. (Sharma et al., 2009). Polycomb Repressive Complex 2 (PRC2) components are well-known epigenetic molecules that maintain a repressed transcriptional state in embryonic chromatin landscapes. These molecules are responsible for several dynamic biological processes, such as cell cycle progression, stem cell plasticity, cell differentiation, proliferation, etc. Of these, Jumonji and AT Rich Interacting Domain2 (JARID2) are among the substantial entities of PRC2. Article History: Received: 09 th Feb., 2024 Accepted: 12 th May, 2024 Published: 30 th May, 2024 Abstract: Jumonji and AT Rich Interacting Domain2 (JARID2) protein is recognized as a pivotal gene among the Polycomb Repressive Complex2 (PRC2) components. Nevertheless, the systematic assessment of JARID2 in cancers will enable us to understand its possible role and mechanism. Therefore, in this study, a pan-cancer analysis of JARID2 in cancers using The Cancer Genome Atlas (TCGA) database was performed. We observed an increased expression of JARID2 mRNA and protein in multiple cancer tissues in comparison to the control. In addition, we showed that the high JARID2 expression was closely associated to the poor overall survival and disease-free survival rate of cancer patients. Moreover, upregulated JARID2 has been observed to be involved in triggering the tumor immune response. To supplement the findings, a differential expression profiling was performed using datasets of RNA-Seq of OSCC tissues, which were obtained from NCBI SRA database. In line with the previous findings, JARID2 was observed to be upregulated in OSCC tissues. The expression pattern was validated in various cancer cell lines using qRT-PCR analysis. Altogether, this study comprehensively demonstrates JARID2 as a possible oncogene in human cancer. Keywords: Bioinformatics, cancer, JARID2, polycomb repressive complex2, transcriptomics How to cite this Article: Bhuvanadas Sreeshma, Habeeb Shaik Mohideen and Arikketh Devi (2024). Integrated Bioinformatics Analysis and Transcriptomics Analysis Predict Jumonji and AT Rich Interacting Domain2 (JARID2) as a Therapeutic Target in Human Cancers. International Journal of Experimental Research and Review, 39(spl.) 15-38. DOI: https://doi.org/10.52756/ijerr.2024.v39spl.002